Targeting Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (TRAIL): A Promising Therapeutic Strategy in Gliomas
作者： George A. Alexiou , Konstantinos I. Tsamis , Athanasios P. Kyritsis
DOI: 10.1016/J.SPEN.2014.12.002
关键词:
摘要: Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) has been increasingly studied for the treatment of gliomas. TRAIL ability to specifically target cancer cells, without any harmful effects on normal and induces apoptosis by interacting with specific receptors. Nevertheless, resistance mechanisms may occur at different points in signaling pathways TRAIL-induced apoptosis. Various approaches have developed overcome resistance. Here, we reviewed known molecular which exerts anticancer activity, possible mechanisms, ways sensitize resistant finally current clinical successes or limitations TRAIL-based therapies.
sempedneurjnl.com参考文章(48)
David A. Schomas, Nadia N. Issa Laack, Ravi D. Rao, Fredric B. Meyer, Edward G. Shaw, Brian Patrick O'Neill, Caterina Giannini, Paul D. Brown, Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-up at Mayo Clinic Neuro-oncology. ,vol. 11, pp. 437- 445 ,(2009) , 10.1215/15228517-2008-102
Kerstin Schultze, Barbara Böck, Anika Eckert, Lena Oevermann, Dirk Ramacher, Otmar Wiestler, Wilfried Roth, Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin. Apoptosis. ,vol. 11, pp. 1503- 1512 ,(2006) , 10.1007/S10495-006-8896-3
R Yu, L Deedigan, S M Albarenque, A Mohr, R M Zwacka, Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects Cell Death and Disease. ,vol. 4, pp. 0- ,(2013) , 10.1038/CDDIS.2013.19
Holger Hetschko, Valerie Voss, Sigrid Horn, Volker Seifert, Jochen H. M. Prehn, Donat Kögel, Pharmacological inhibition of Bcl-2 family members reactivates TRAIL-induced apoptosis in malignant glioma Journal of Neuro-Oncology. ,vol. 86, pp. 265- 272 ,(2008) , 10.1007/S11060-007-9472-6
Xing Li, Qinwen Mao, Dongyang Wang, Weifeng Zhang, Haibin Xia, A fiber chimeric CRAd vector Ad5/11-D24 double-armed with TRAIL and arresten for enhanced glioblastoma therapy. Human Gene Therapy. ,vol. 23, pp. 589- 596 ,(2012) , 10.1089/HUM.2011.130
I Verbrugge, E De Vries, SWG Tait, EHJ Wissink, H Walczak, M Verheij, J Borst, None, Ionizing radiation modulates the TRAIL death-inducing signaling complex, allowing bypass of the mitochondrial apoptosis pathway. Oncogene. ,vol. 27, pp. 574- 584 ,(2008) , 10.1038/SJ.ONC.1210696
Jos MA Kuijlen, Jan Jakob A Mooij, Inge Platteel, Eelco W Hoving, Winette TA van der Graaf, Mark M Span, Harry Hollema, Wilfred FA den Dunnen, TRAIL-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme. Journal of Neuro-oncology. ,vol. 78, pp. 161- 171 ,(2006) , 10.1007/S11060-005-9081-1
P. Mitlianga, C. Sioka, G. Vartholomatos, A. Goussia, K. Polyzoidis, J. Rao, A. Kyritsis, p53 enhances the Δ-24 conditionally replicative adenovirus anti-glioma effect Oncology Reports. ,vol. 15, pp. 149- 153 ,(2006) , 10.3892/OR.15.1.149
Chuanjiang Huang, Yinan Luo, Jingwei Zhao, Fuwei Yang, Hongwei Zhao, Wenhai Fan, Pengfei Ge, Shikonin Kills Glioma Cells through Necroptosis Mediated by RIP-1 PLoS ONE. ,vol. 8, pp. e66326- ,(2013) , 10.1371/JOURNAL.PONE.0066326
Thomas Unterkircher, Silvia Cristofanon, Sri Hari Krishna Vellanki, Lisa Nonnenmacher, Georg Karpel-Massler, Christian Rainer Wirtz, Klaus-Michael Debatin, Simone Fulda, Bortezomib Primes Glioblastoma, Including Glioblastoma Stem Cells, for TRAIL by Increasing tBid Stability and Mitochondrial Apoptosis Clinical Cancer Research. ,vol. 17, pp. 4019- 4030 ,(2011) , 10.1158/1078-0432.CCR-11-0075